Kronos Bio (NASDAQ:KRON – Get Rating) had its price target cut by research analysts at Piper Sandler from $13.00 to $7.00 in a report released on Wednesday, The Fly reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 173.44% from the stock’s previous close.
Separately, Berenberg Bank initiated coverage on Kronos Bio in a research report on Wednesday, September 14th. They issued a “buy” rating and a $12.00 target price for the company.
Kronos Bio Price Performance
Shares of NASDAQ KRON opened at $2.56 on Wednesday. Kronos Bio has a 1-year low of $2.28 and a 1-year high of $17.49. The business has a 50-day moving average of $3.42 and a 200-day moving average of $3.97. The company has a market capitalization of $145.33 million, a price-to-earnings ratio of -0.87 and a beta of 1.29.
Institutional Inflows and Outflows
Kronos Bio Company Profile
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
- Get a free copy of the StockNews.com research report on Kronos Bio (KRON)
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Coupang Stock And Why You Should Care
- This Is No Time To Buy D.R. Horton Stock
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.